SG11201610745XA - Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases - Google Patents
Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinasesInfo
- Publication number
- SG11201610745XA SG11201610745XA SG11201610745XA SG11201610745XA SG11201610745XA SG 11201610745X A SG11201610745X A SG 11201610745XA SG 11201610745X A SG11201610745X A SG 11201610745XA SG 11201610745X A SG11201610745X A SG 11201610745XA SG 11201610745X A SG11201610745X A SG 11201610745XA
- Authority
- SG
- Singapore
- Prior art keywords
- delta
- protein kinases
- dual inhibitors
- gamma protein
- selective dual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/38—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reaction of ammonia or amines with sulfonic acids, or with esters, anhydrides, or halides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3144CH2014 | 2014-06-27 | ||
PCT/IB2015/054844 WO2015198289A1 (en) | 2014-06-27 | 2015-06-26 | Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201610745XA true SG11201610745XA (en) | 2017-01-27 |
Family
ID=53761447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201610745XA SG11201610745XA (en) | 2014-06-27 | 2015-06-26 | Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases |
Country Status (18)
Country | Link |
---|---|
US (4) | US9708329B2 (en) |
EP (1) | EP3160968B1 (en) |
JP (1) | JP6557266B2 (en) |
KR (1) | KR20170016489A (en) |
CN (1) | CN106661029B (en) |
AP (1) | AP2017009670A0 (en) |
AU (1) | AU2015278699B2 (en) |
CA (1) | CA2951370A1 (en) |
CL (1) | CL2016003328A1 (en) |
CO (1) | CO2017000687A2 (en) |
DK (1) | DK3160968T3 (en) |
EA (1) | EA031135B1 (en) |
ES (1) | ES2708748T3 (en) |
IL (1) | IL249740A0 (en) |
MX (1) | MX2016016892A (en) |
PH (1) | PH12016502572A1 (en) |
SG (1) | SG11201610745XA (en) |
WO (1) | WO2015198289A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190052A1 (en) | 2016-09-22 | 2019-03-21 | Astrazeneca Ab | 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 h-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma |
WO2021242859A1 (en) * | 2020-05-27 | 2021-12-02 | Duke University | Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy |
CN114258393A (en) * | 2020-07-21 | 2022-03-29 | 中国医药研究开发中心有限公司 | Heterocyclic compound with dual phosphatidylinositol 3-kinase delta and gamma inhibitor activity and medical application thereof |
CN114891005B (en) * | 2022-03-30 | 2024-01-19 | 武汉九州钰民医药科技有限公司 | Preparation process of Wupalision p-toluenesulfonate |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998014449A1 (en) * | 1996-10-02 | 1998-04-09 | Novartis Ag | Fused pyrazole derivatives and processes for their preparation |
MX352661B (en) * | 2009-11-05 | 2017-12-04 | Rhizen Pharmaceuticals S A Star | Novel benzopyran kinase modulators. |
JP5099570B2 (en) | 2010-07-12 | 2012-12-19 | 国立大学法人鳥取大学 | New hiPSC production method by siRNA introduction |
WO2012121953A1 (en) | 2011-03-08 | 2012-09-13 | The Trustees Of Columbia University In The City Of New York | Methods and pharmaceutical compositions for treating lymphoid malignancy |
WO2012131953A1 (en) | 2011-03-30 | 2012-10-04 | トヨタ自動車株式会社 | In-wheel motor vehicle |
PL2705029T4 (en) | 2011-05-04 | 2019-04-30 | Rhizen Pharmaceuticals S.A. | Novel compounds as modulators of protein kinases |
AP3547A (en) | 2012-05-04 | 2016-01-14 | Rhizen Pharmaceuticals Sa | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals |
PL2870157T3 (en) * | 2012-07-04 | 2018-01-31 | Rhizen Pharmaceuticals S A | Selective pi3k delta inhibitors |
CN105431437B (en) * | 2013-07-02 | 2020-03-10 | 理森制药股份公司 | PI3K protein kinase inhibitors, in particular delta inhibitors and/or gamma inhibitors |
-
2015
- 2015-06-26 MX MX2016016892A patent/MX2016016892A/en active IP Right Grant
- 2015-06-26 SG SG11201610745XA patent/SG11201610745XA/en unknown
- 2015-06-26 EA EA201692297A patent/EA031135B1/en unknown
- 2015-06-26 DK DK15744357.3T patent/DK3160968T3/en active
- 2015-06-26 AU AU2015278699A patent/AU2015278699B2/en not_active Ceased
- 2015-06-26 JP JP2016575454A patent/JP6557266B2/en not_active Expired - Fee Related
- 2015-06-26 US US14/752,243 patent/US9708329B2/en active Active
- 2015-06-26 EP EP15744357.3A patent/EP3160968B1/en not_active Not-in-force
- 2015-06-26 AP AP2017009670A patent/AP2017009670A0/en unknown
- 2015-06-26 WO PCT/IB2015/054844 patent/WO2015198289A1/en active Application Filing
- 2015-06-26 ES ES15744357T patent/ES2708748T3/en active Active
- 2015-06-26 CA CA2951370A patent/CA2951370A1/en not_active Abandoned
- 2015-06-26 CN CN201580034240.6A patent/CN106661029B/en not_active Expired - Fee Related
- 2015-06-26 KR KR1020177000926A patent/KR20170016489A/en not_active Application Discontinuation
-
2016
- 2016-12-21 PH PH12016502572A patent/PH12016502572A1/en unknown
- 2016-12-22 IL IL249740A patent/IL249740A0/en unknown
- 2016-12-26 CL CL2016003328A patent/CL2016003328A1/en unknown
-
2017
- 2017-01-26 CO CONC2017/0000687A patent/CO2017000687A2/en unknown
- 2017-04-05 US US15/480,181 patent/US10179786B2/en not_active Expired - Fee Related
-
2018
- 2018-12-06 US US16/212,447 patent/US20190202836A1/en not_active Abandoned
-
2020
- 2020-03-05 US US16/810,219 patent/US20200199133A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK3160968T3 (en) | 2019-02-18 |
US20150376188A1 (en) | 2015-12-31 |
IL249740A0 (en) | 2017-02-28 |
US10179786B2 (en) | 2019-01-15 |
JP2017526631A (en) | 2017-09-14 |
NZ727214A (en) | 2021-08-27 |
AU2015278699A1 (en) | 2017-01-05 |
CA2951370A1 (en) | 2015-12-30 |
WO2015198289A1 (en) | 2015-12-30 |
AP2017009670A0 (en) | 2017-01-31 |
CL2016003328A1 (en) | 2017-12-01 |
US20200199133A1 (en) | 2020-06-25 |
EP3160968A1 (en) | 2017-05-03 |
CN106661029B (en) | 2019-04-05 |
US9708329B2 (en) | 2017-07-18 |
US20170204106A1 (en) | 2017-07-20 |
MX2016016892A (en) | 2017-07-28 |
CN106661029A (en) | 2017-05-10 |
ES2708748T3 (en) | 2019-04-11 |
US20190202836A1 (en) | 2019-07-04 |
PH12016502572A1 (en) | 2017-04-17 |
AU2015278699B2 (en) | 2019-10-31 |
JP6557266B2 (en) | 2019-08-07 |
EA201692297A1 (en) | 2017-06-30 |
KR20170016489A (en) | 2017-02-13 |
CO2017000687A2 (en) | 2017-06-09 |
EA031135B1 (en) | 2018-11-30 |
EP3160968B1 (en) | 2018-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181650T1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
PL3218378T3 (en) | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | |
ZA201700786B (en) | Protein kinase c inhibitors and methods of their use | |
IL257061A (en) | Inhibitors of ezh2 | |
HK1250161B (en) | 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors | |
EP3265093A4 (en) | Tricyclic kinase inhibitors of melk and methods of use | |
EP3194377A4 (en) | Heterocycle substituted amino-pyridine compounds and methods of use thereof | |
EP3183256A4 (en) | Substituted macrocycles useful as kinases inhibitors and methods of use thereof | |
HK1250028A1 (en) | 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors | |
IL258438B (en) | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors | |
IL249740A0 (en) | Selective dual inhibitors of pi3 delta and gamma protein kinases | |
PL3362450T3 (en) | N1- and n7-substituted sibiriline derivatives and their use as inhibitors of cellular necroptosis | |
IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors |